✦ LIBER ✦

GSK-3 inhibition in vitro and in vivo enhances antitumor effect of sorafenib in renal cell carcinoma (RCC)

✍ Scribed by Hisashi Kawazoe; Vladimir N. Bilim; Andrey V. Ugolkov; Kaori Yuuki; Sei Naito; Akira Nagaoka; Tomoyuki Kato; Yoshihiko Tomita

Book ID: 116303565
Publisher: Elsevier Science
Year: 2012
Tongue: English
Weight: 739 KB
Volume: 423
Category: Article
ISSN: 0006-291X
DOI: 10.1016/j.bbrc.2012.05.147

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Nutlin-3 enhances sorafenib efficacy in

Nutlin-3 enhances sorafenib efficacy in renal cell carcinoma

✍ Rit Vatsyayan; Jyotsana Singhal; Lokesh Dalasanur Nagaprashantha; Sanjay Awasthi 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 580 KB

Inhibition of angiogenic and non-angioge

Inhibition of angiogenic and non-angiogenic targets by sorafenib in renal cell carcinoma (RCC) in a RCC xenograft model

✍ Yuen, J S P; Sim, M Y; Siml, H G; Chong, T W; Lau, W K O; Cheng, C W S; Huynh, H 📂 Article 📅 2011 🏛 Nature Publishing Group 🌐 English ⚖ 628 KB

GSK-3 IS A POTENTIAL THERAPEUTIC TARGET

GSK-3 IS A POTENTIAL THERAPEUTIC TARGET FOR THE TREATMENT OF RENAL CELL CARCINOMA (RCC): PRECLINICAL IN VITRO AND IN VIVO INVESTIGATION

✍ Kawazoe, Hisashi; Bilim, Vladimir; Yuuki, Kaori; Muto, Akinori; Ougolkov, Andrei 📂 Article 📅 2009 🏛 Lippincott Williams and Wilkins 🌐 English ⚖ 92 KB

Synergistic antitumor effect of ionomyci

Synergistic antitumor effect of ionomycin and cisplatin against renal cell carcinoma in vitro and in vivo

✍ Masayuki Okamoto; Isao Hara; Hideaki Miyake; Shoji Hara; Akinobu Gotoh; Soichi A 📂 Article 📅 2001 🏛 Elsevier Science 🌐 English ⚖ 264 KB

298 CLUSTERIN INHIBITION USING OGX-011 S

298 CLUSTERIN INHIBITION USING OGX-011 SYNERGISTICALLY ENHANCES ANTITUMOR ACTIVITY OF SORAFENIB IN A HUMAN RENAL CELL CARCINOMA MODEL

✍ Kusuda, Yuji; Miyake, Hideaki; Gleave, Martin; Fujisawa, Masato 📂 Article 📅 2012 🏛 Lippincott Williams and Wilkins 🌐 English ⚖ 50 KB

Vitamin K enhancement of sorafenib-media

Vitamin K enhancement of sorafenib-mediated HCC cell growth inhibition in vitro and in vivo

✍ Gang Wei; Meifang Wang; Terry Hyslop; Ziqiu Wang; Brian I. Carr 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 French ⚖ 775 KB

## Abstract The multikinase inhibitor sorafenib is the first oral agent to show activity against human hepatocellular carcinoma (HCC). Apoptosis has been shown to be induced in HCC by several agents, including sorafenib as well as by the naturally occurring K vitamins (VKs). As few nontoxic agents